SHARE:   Share to Facebook Share to Twitter Share to Linked In Share via Email  

Back To Search Results

S17 - Movement Disorders: Ataxia and the Cerebellum

Event Time: Monday April 24, 2017 3:30 pm to 5:30 pm
Topic(s): Movement Disorders
Description: A group of abstracts covering a similar topic presented in an oral format. Presentations are eight minutes in length with four minutes of question and answer. Each session concludes with 25 minutes of a discussant bringing additional context to one or more of the abstracts.
Completion Message:
CME Credits: 2
Core Competencies:

Program Speakers - Tentative

Start/End Time Title Faculty
5:05 PM - 5:30 PM Discussion Brent Fogel MD, PhD, FAAN 


Speaker Disclosure
Brent L. Fogel, MD, PhD, FAAN Dr. Fogel has nothing to disclose.

Abstract Presenters

Start Time Pub. Title Presenter
3:30 PM 001 ATXN2 antisense therapy improves SCA2 mouse motor and Purkinje cell electrophysiological phenotypes. Daniel Scoles, PhD
Dr. Scoles has nothing to disclose.

3:42 PM 002 Fragile X Gray Zone Alleles are associated with Better Global Motor Function in an Elderly Community Population Deborah Hall, MD, PhD, FAAN
Dr. Hall has received personal compensation in an editorial capacity for American Academy of Neurology . Dr. Hall has received research support from Neurocrine, Pfizer, and Abbvie.

3:54 PM 003 RT001 First-in Human Clinical Trial Demonstrates Safety, Favorable Pharmacokinetics, and Early Signals of Efficacy in Friedreich’s Ataxia Theresa Zesiewicz, MD, FAAN
Dr. Zesiewicz has nothing to disclose.

4:06 PM 004 Exome Sequencing Offers a Comprehensive Genetic Evaluation and High Diagnostic Rate for Ataxia-related Disorders Francisca Millan
Dr. Millan has received personal compensation for activities with GeneDx as an employee.

4:18 PM 005 EPI-743 (Alpha-tocotrienol Quinone) Demonstrates Long-Term Improvement in Neurological Function and Disease Progression in Friedreich's Ataxia Theresa Zesiewicz
Dr. Zesiewicz has nothing to disclose.

4:30 PM 006 Cerebellar Pathology in Early Onset and Late Onset Essential Tremor Sheng-Han Kuo, MD
Dr. Kuo has nothing to disclose.

4:42 PM 007 Structure-Phenotype relationships in ATP1A3 (Na,K-ATPase) diseases Kathleen J Sweadner
Dr. Sweadner has nothing to disclose.

4:54 PM 008 In vivo drug discovery for progressive supranuclear palsy using a novel zebrafish model Qing Bai
Dr. Burton has nothing to disclose.

Register Now

Related Courses

Saturday April 21, 2018

7:00 AM-9:00 AM
C4 Hyperkinetic Movement Disorders: Videodiagnosis and Treatment Steven Frucht MD
9:30 AM-11:30 AM
C14 Parkinson's Disease Update Melissa Nirenberg MD, PhD, FAAN
1:30 PM-3:30 PM
C23 Diagnosis and Treatment of Functional Movement Disorders Mark Hallett MD, FAAN

Sunday April 22, 2018

7:00 AM-9:00 AM
C24 Hot Topics and Controversies in Parkinson's Disease Melissa Nirenberg MD, PhD, FAAN
1:00 PM-3:00 PM
C36 Nonmotor Manifestations of Parkinson's Disease I Charles Adler MD, PhD, FAAN
3:30 PM-5:30 PM
C50 Nonmotor Manifestations of Parkinson's Disease II Charles Adler MD, PhD, FAAN

Monday April 23, 2018

7:00 AM-9:00 AM
C65 Video EEG: Name That Spell Amy Crepeau MD
C58 Balance and Gait Disorders Bastiaan Bloem MD, PhD
1:00 PM-3:00 PM
C67 Evaluating Tremor in the Office Vicki Shanker MD

Wednesday April 25, 2018

7:00 AM-9:00 AM
C140 Paroxysmal Movement Disorders Kailash Bhatia MD, FAAN
1:00 PM-5:30 PM
C159 Clinical Uses of Botulinum Toxin for Dystonia Skills Workshop Diego Torres-Russotto MD, FAAN

Thursday April 26, 2018

7:00 AM-9:00 AM
C176 The Dystonia: Diagnosis, Treatment and Update on Etiologies Rachel Saunders-Pullman MD
1:00 PM-3:00 PM
C187 Cerebellar and Afferent Ataxias: Diagnosis and Management Massimo Pandolfo MD, FAAN
3:30 PM-5:30 PM
C209 Clinical Usefulness of Botulinum Toxin for Spasticity Skills Workshop Allison Brashear MD, MBA, FAAN
6:30 PM-9:30 PM
C213 Case Studies: Unusual Movement Disorders Kailash Bhatia MD, FAAN


Forgot Password?